HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2006.037606v1 60/3/283    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Higashiyama, H. Articles by Kinoshita, M. Search for Related Content PubMed PubMed Citation Articles by Higashiyama, H. Articles by Kinoshita, M.

Receptor-activated Smad localisation in Bleomycin-induced pulmonary fibrosis

Department of Pharmacology, Tsukuba Research Laboratories, GlaxoSmithKline, Tsukuba, Ibaraki, Japan

Correspondence to:
Dr S Asano
Department of Pharmacology, Tsukuba Research Laboratories, GlaxoSmithKline, 43 Wadai, Tsukuba, Ibaraki 300-4247, Japan;satoshi.asano{at}gsk.com Background: Recent advances in fibrosis biology have identified transforming growth factor (TGF)-ß type I receptor-mediated activation of Smads as playing a central part in the development of fibrosis. However, to date, there have been few studies that examined the localisation and distribution of receptor-activated Smads protein (R-Smads: Smad2 and 3) during the fibrosis progression.

Aims: To histopathologically assess the time-course change of the localisation and distribution of the Smads protein in pulmonary fibrosis.

Methods: Pulmonary fibrosis was induced by intranasal injection of bleomycin (0.3 U/mouse). Lungs were isolated 2, 5, 7, 9 and 14 days after bleomycin treatment. Histological changes in the lungs were evaluated by haematoxylin-eosin stain or Masson’s trichrome stain, and scored. TGF-ß1, Smad3 and phosphorylated Smad2 localisations in lung tissues were determined by immunohistochemistry.

Results: The bleomycin treatment led to considerable pulmonary fibrotic changes accompanied by marked increase in TGF-ß1 expression in infiltrating macrophages. With the progression in fibrosis (day 7–14), marked increases in Smad3-positive and pSmad2-positive cells were observed. There were intense Smad3-positive and pSmad2-positive signals localised to the nuclei of the infiltrating macrophages and to type II epithelial cells, and less intense signals in fibroblasts and hyperplastic alveolar/bronchiolar epithelial cells.

Conclusions: The time-course data of TGF-ß1 and R-Smads indicate that progressive enhancement of TGF-ß1 signalling via R-Smad is activated in the process of fibrosis progression.